Czech medtech Carebot secures €1.5M for AI scan tools

Czech medtech startup Carebot has raised €1.5 million, its largest funding round to date, to expand its AI-powered diagnostic tools. The raise, reported by AroundPrague.cz, comes as the company aims to grow beyond its home market.

The €1.5 million figure—equivalent to 36 million Czech koruna—places Carebot alongside other European AI healthcare startups, though it is significantly smaller than the funding secured by some peers. Recent StartupReader coverage has highlighted rounds in the hundreds of millions for companies like Harvey and Instinct, while Carebot’s valuation has not been disclosed. This difference may reflect varying stages of development or investor expectations in the sector.

Carebot’s product is designed to assist with medical scan analysis, though specifics about its technology, regulatory status, or customer adoption are not included in the announcement. Whether this funding will be enough to compete with better-resourced competitors or if Carebot will need additional capital remains an open question.

The raise coincides with broader trends in AI healthcare, where startups face challenges around accuracy, regulatory compliance, and integration. Other AI startups recently covered by StartupReader, such as Apate.AI and AI Score, operate in different niches—scam prevention and enterprise governance—highlighting the varied applications of AI in healthcare beyond diagnostics.

Notable gaps in Carebot’s announcement include details on revenue, customer base, or regulatory approvals, which would help assess its progress. CEO Matěj Misař has framed the funding as a step toward growth, but without further metrics, it’s difficult to determine whether €1.5 million will be sufficient for the company’s next phase.

The round also reflects the uneven distribution of capital in AI healthcare. While some startups raise hundreds of millions, others, like Carebot, operate on a smaller scale. The path to commercialization in this sector often requires significant investment, and Carebot’s funding may or may not be enough to sustain its ambitions.

What to watch next: whether Carebot can use this capital to achieve regulatory milestones, secure paying customers, or attract further investment. If not, the €1.5 million round may mark a modest step rather than a breakthrough in Europe’s AI healthcare landscape.

Sources: aroundprague.cz